Board of Directors

Anne co-founded 23andMe in 2006, three years after the first human genome was sequenced. Her goal was audacious: to help people access, understand, and benefit from the human genome and fundamentally change healthcare in the process. Prior to founding 23andMe, Anne spent a decade on Wall Street investing in healthcare and felt frustrated by a system built around monetizing illness instead of incentivizing prevention. She wanted to flip that model on its head and build a business that helps people prevent illness rather than profit from it. Anne focused on empowering people with direct access to genetic information so that they could use their data to make decisions that could lower their risks for disease. Under her leadership, 23andMe now provides the only personal genetic test with FDA authorization to deliver health information directly to consumers.

From the beginning, Anne's goal and 23andMe’s mission has not wavered. Along with empowering consumers with health information, Anne wanted 23andMe to transform how research discoveries are made and revolutionize the development of treatments for disease. By inviting people to participate in research, 23andMe is able to crowdsource billions of data points resulting in the world’s largest resource for genetic research. This novel, web-based approach has already resulted in thousands of new genetic insights and allows 23andMe to rapidly recruit participants to multiple studies at once, reducing the time and resources needed to make discoveries and is integral to 23andMe’s mission of understanding and benefiting from the human genome This new approach to research also powers 23andMe’s therapeutics group, which is helping to translate this knowledge into new treatments for serious unmet medical needs. In line with this, 23andMe is now also using its unique model to speed recruitment for clinical trials.

Anne is a pioneer in the direct-to-consumer DNA testing space and her vision and persistence have allowed 23andMe to provide people with unprecedented access to genetic information. Through its research platform, 23andMe has brought personalized medicine directly to millions of consumers.

Anne graduated from Yale University with a BS in Biology.

Mr. Jensen has substantial financial and corporate governance experience, having served as an advisor and board member in various companies in the technology sector. Prior to his retirement in 2012, Mr. Jensen was an executive at Deloitte & Touche LLP (“Deloitte”), where he served as U.S. Managing Partner-Audit and Enterprise Risk Services, Technology Industry and U.S. Managing Partner-Venture Capital Services Group. Before Deloitte, Mr. Jensen was the Chief Financial Officer at Redleaf Group, as well as an executive at the accounting firm Arthur Andersen LLP, where he was the Managing Partner of the Silicon Valley Office and led the company’s Global Technology Industry Practice. Mr. Jensen currently serves on the Board of Directors and Chair of the Audit Committee of Lattice Semiconductor Corporation (Nasdaq: LSCC).

Mr. Fernandez, a seasoned executive with extensive cross-industry leadership experience, most recently served as the Chief Financial Officer of WeWork, Inc. Prior to joining WeWork, Inc., he was the Executive Vice President and Chief Financial Officer of NCR Corporation, a global enterprise technology provider of digital commerce solutions for financial institutions, retail stores, and restaurants, and the President and Chief Executive Officer of CBS Radio Inc. Mr. Fernandez currently serves on the Board of Directors and the Audit Committee of Cardlytics, Inc. (Nasdaq: CDLX).

A practiced leader and advisor in the technology space, Mr. Frankola most recently served as the Chief Financial Officer and a strategic advisor to Cloudera, Inc., an enterprise data cloud company. Prior to Cloudera, Inc., Mr. Frankola was the Chief Financial Officer of Yodlee, Inc., a data aggregation and analytics platform, and Ariba, Inc., a leading procurement and supply chain management technology provider. He currently serves on the Board of Directors and Chair of the Audit Committee of Ansys, Inc. (Nasdaq: ANSS) and on the Board of Directors and the Audit Committee of Skillsoft Corp. (NYSE: SKIL). Additionally, Mr. Frankola is an advisor to the artificial intelligence companies Vectara and Narada.